Company intelligence / Profile preview

Eyevensys

Paris, Ile-de-France, Francepulsesight.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 1

Overview

Eyevensys has validated its proprietary nonviral gene therapy ocular drug delivery platform in the clinic with EYS606 for non-infectious uveitis. The company’s pipeline includes programs targeting wet AMD and retinitis pigmentosa. Its approach enables sustained intraocular production of therapeutic proteins via electroporation-mediated plasmid delivery to the ciliary muscle, turning the eye into a local biofactory. EYS606 received orphan designation from EMA and regulatory clearance to begin Phase I/II trials in France and UK. The company recently raised $12M to accelerate development of its next-generation programs.

Therapeutic areas: Ophthalmology
Modalities: Non-viral gene therapy (plasmid DNA)Protein therapeutics (via in vivo expression)
Industry: Biotech

Drug pipeline

3 assets

EYS606

2 more assets in the full pipeline.

Request access →

Partnerships

Korea Investment Partners led recent funding round; no major pharma partnerships disclosed as of latest reports

Beyond the preview

Go deeper on Eyevensys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eyevensys.

Explore the full profile